Swissmedic Authorizes Novavax COVID-19 Vaccine For Adolescents And As Booster In Adults

Novavax Inc. (NVAX) said that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland for active immunization to prevent COVID-19 caused by the SARS-CoV-2 in adolescents aged 12 through 17 and as a heterologous and homologous booster dose for adults aged 18 and older.

The company said it has ongoing trials further exploring Nuvaxovid's efficacy and safety as a booster and preclinical data suggest that its vaccine induces immune response against Omicron variants, including BA.4/5.

The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT